• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Recent acquisition fixation requires regulatory guidance


In the first half of this year, there have been several significant business transactions in the managed care industry that have either been completed or announced. Just to name a few, Anthem and WellPoint Health Networks are merging; UnitedHealthcare acquired Mid-Atlantic Medical Services; Humana acquired Ochsner Health Plan; UnitedHealthcare announced the acquisition of Oxford Health Plans; and Molina Healthcare announced its acquisition of Cimarron Health Plan. In this highly regulated industry, these types of transactions require various regulatory approvals. With so much activity this year, it is important to highlight some of the necessary procedures for potential acquirers and targets.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.